The EMA’s CHMP has adopted a positive opinion recommending the full marketing authorization for Hepcludex in adults with chronic HDV & compensated liver disease
The opinion was based on P-III (MYR301) 48wk. study evaluating bulevirtide in 150 patients, showed a positive impact of bulevirtide on PROs with a greater combined virological & biochemical response (45% & 48%) over patients who had not received antiviral treatment (2%). The safety profile was consistent with prior reports with no patients having AE leading to discontinuation of bulevirtide
Hepcludex will be the only approved treatment for HDV in the EU if granted by the EC. The company also works with multiple regulatory authorities on marketing applications for bulevirtide in other parts of the world
Ref: BusinessWire | Image: Gilead
Related News:- Gilead Presents 48 Week Results of Hepcludex (bulevirtide) in P-III (MYR301) Trial for the Treatment of Chronic Hepatitis Delta Virus at ILC 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
